With its four (4) comprehensive lines of services, IPS Therapeutique primarily intends to provide drug developers with regulatory safety prerequisites needed to move to clinical testing, but also to offer biopharmaceutical decision-makers rapid and cost effective solutions to improve the outcome of their drug development programs.

Each line of services regroups cardiotoxicity assays which incrementally focus on specific issues or mechanisms that need to be investigated, using different or complementary approaches adapted to a specific compound. All assays within the same class of services also tend to share an optimal timing along the drug development process.

Choose the class of services which best fits your needs...

• Safe Lead Select^TM... choose your safest lead candidate(s) earlier and with more confidence to cut on development costs.

• IND-Enabler^TM... to ensure a prompt and seamless IND approval by regulatory authorities.

• Torsades Predict^TM... beyond regulatory requirements, and into the mechanisms of QT Prolongation.

• Human Cardiac Efficacy models... to support and/or validate your cardiovascular efficacy data.

Click on the graph below to visualize the ideal timing for each line of services.